OA09415A - "Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique". - Google Patents

"Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique".

Info

Publication number
OA09415A
OA09415A OA59551A OA59551A OA09415A OA 09415 A OA09415 A OA 09415A OA 59551 A OA59551 A OA 59551A OA 59551 A OA59551 A OA 59551A OA 09415 A OA09415 A OA 09415A
Authority
OA
OAPI
Prior art keywords
derivative
pharmaceutical composition
oral administration
diphosphonic acid
administration based
Prior art date
Application number
OA59551A
Other languages
English (en)
French (fr)
Inventor
Fels Jean-Pierre
Gromenil Jean-Claude
Abramovici Bernard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9365083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA09415(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of OA09415A publication Critical patent/OA09415A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA59551A 1988-04-07 1989-04-07 "Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique". OA09415A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8804628A FR2629716B1 (fr) 1988-04-07 1988-04-07 Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique

Publications (1)

Publication Number Publication Date
OA09415A true OA09415A (fr) 1992-10-15

Family

ID=9365083

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59551A OA09415A (fr) 1988-04-07 1989-04-07 "Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique".

Country Status (15)

Country Link
US (1) US4980171A (xx)
EP (1) EP0336851B1 (xx)
JP (1) JP2602947B2 (xx)
KR (1) KR0135420B1 (xx)
AU (1) AU618796B2 (xx)
CA (1) CA1327009C (xx)
DE (1) DE68900994D1 (xx)
DK (1) DK166989A (xx)
FR (1) FR2629716B1 (xx)
IE (1) IE60923B1 (xx)
IL (1) IL89868A (xx)
NZ (1) NZ228617A (xx)
OA (1) OA09415A (xx)
PH (1) PH26647A (xx)
ZA (1) ZA892557B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
DK0625355T5 (da) * 1993-05-15 2003-12-01 Roche Diagnostics Gmbh Tablet med forbedret biotilgængelighed indeholdende dichlormethylendiphosphonsyre som virksomt stof
ES2118445T3 (es) * 1993-10-26 1998-09-16 Akzo Nobel Nv Acidos aminoalcano-difosfonicos en blanqueo de pasta papelera.
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
CN1372468A (zh) * 1999-06-02 2002-10-02 宝洁公司 羟乙磷酸二钠口服制剂
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
ES2243457T3 (es) * 2001-01-23 2005-12-01 Gador S.A. Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma.
CA2480814A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
ATE369139T1 (de) 2002-12-20 2007-08-15 Hoffmann La Roche Hochdosierte ibandronat-formulierung
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
ES2507552T3 (es) * 2005-10-27 2014-10-15 Nexilis Ag Implante que contiene amino-bisfosfonatos y procedimiento para su producción
US8940320B2 (en) * 2005-10-27 2015-01-27 Thommen Medical Ag Dental implant and production method for said implant
EP1903037A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
FR2954320B1 (fr) * 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
FR2975300B1 (fr) * 2011-05-19 2013-06-07 Thierry Breul Composition pharmaceutique a biodisponibilite amelioree
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
EP3689202A1 (en) 2017-08-09 2020-08-05 SharkNinja Operating LLC Cooking device and components thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534390C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1,3-Di-aminoalkan-1,1-diphosphonsäuren
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
US4330530A (en) * 1980-12-22 1982-05-18 The Procter & Gamble Company Anti-arthritic compositions and method using gold salts and organophosphonates
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
GB2135879B (en) * 1983-03-07 1986-05-21 Ciba Geigy Ag Pharmaceutical preparations with uniform elution properties
US4902679A (en) * 1985-12-13 1990-02-20 Norwich Eaton Pharmaceuticals, Inc. Methods of treating diseases with certain geminal diphosphonates

Also Published As

Publication number Publication date
IE891103L (en) 1989-10-07
NZ228617A (en) 1992-02-25
CA1327009C (en) 1994-02-15
FR2629716B1 (fr) 1991-07-19
IE60923B1 (en) 1994-09-07
EP0336851B1 (fr) 1992-03-18
IL89868A0 (en) 1989-12-15
FR2629716A1 (fr) 1989-10-13
JPH026409A (ja) 1990-01-10
KR890015738A (ko) 1989-11-25
AU3258889A (en) 1989-10-12
DK166989D0 (da) 1989-04-06
ZA892557B (en) 1989-12-27
EP0336851A1 (fr) 1989-10-11
KR0135420B1 (ko) 1998-04-23
PH26647A (en) 1992-09-04
AU618796B2 (en) 1992-01-09
JP2602947B2 (ja) 1997-04-23
IL89868A (en) 1993-08-18
DE68900994D1 (de) 1992-04-23
US4980171A (en) 1990-12-25
DK166989A (da) 1989-10-08

Similar Documents

Publication Publication Date Title
OA09415A (fr) "Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique".
DZ1077A1 (fr) Nouvelles préparation pharmaceutique pour administration orale.
BE849632A (fr) Composition pharmaceutique pour l'administration orale
IT8621358A0 (it) Composizione farmaceutica adattivita' analgesica.
PT87422A (pt) Procede de preparation d'une forme de dosage solide pharmaceutque a base de cimetidine
PT90120B (pt) Processo para a preparacao de uma composicao farmaceutica contendo deprenil para administracao sistemica transdermica
FR2508318B1 (fr) Bandage pour l'administration d'une substance pharmaceutique
FR2552993B1 (fr) Composition pharmaceutique ophtalmique a base d'un derive d'acide phenylacetique
FR2613624B1 (fr) Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
FR2617714B1 (fr) Composition pharmaceutique a base d'analogues de la somatostatine
FR2688405B1 (fr) Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant.
MA22443A1 (fr) Procede de preparation d'une composition pharmaceutique .
FR2499408B1 (fr) Composition pharmaceutique pour le traitement de l'osteopathie, a base d'acide 6-amino-1-hydroxyhexane-1,1-diphosphonique
FR2614790B1 (fr) Nouvelle composition ophtalmologique a base d'acide eicosapeutaenoique
PT88682A (pt) A process for the preparation of pharmaceutical compositions containing a piperidinoalkanol-decongestant combination
OA08430A (fr) Composition fongicide à base d'un dérivé de l'acide phosphoreux.
FR2624736B1 (fr) Nouvelles compositions pharmaceutiques dispersibles dans l'eau a base d'ornidazole
FR2544198B1 (fr) Compositions pharmaceutiques topiques a base d'acide meclophenamique
FR2585953B1 (fr) Composition pharmaceutique pour l'administration orale contenant de l'ubiquinone et procede
IT8619162A0 (it) Composti acilamminoalcanoilici adattivita' farmaceutica.
IT1223132B (it) Composizione farmaceutica per somministrazione nasale
BE877703A (fr) Compositions pharmaceutiques a base de trimethoprim et de derives d'acide n-ethyl- -pyridone-3-carboxylique
FR2594334B1 (fr) Composition pharmaceutique injectable a base d'amoxicilline
FR2668707B1 (fr) Procede de preparation d'une composition pharmaceutique.
FR2586351B1 (fr) Composition pharmaceutique a base de peroxodiphosphate pour l'inactivation d'endotoxines bacteriennes